Crossmark

JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models

Crossref DOI link: https://doi.org/10.1038/s41416-026-03411-3

Published Online: 2026-05-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kang, Min Sil

Katuwal, Nar Bahadur

Ghosh, Mithun

Hong, Sa Deok

Jeong, Yeong Gyu

Park, Seong Min

Kim, Tae Hoen

Kim, Seul-Gi

Lee, Seung Ryeol

Moon, Yong Wha https://orcid.org/0000-0002-7943-974X
Funding

Funding for this research was provided by:

National Research Foundation of Korea (NRF-2021R1C1C1006882)

National Research Foundation of Korea (NRF-2021R1A6A3A01086364)
License Information

Text and Data Mining valid from 2026-05-06

Version of Record valid from 2026-05-06
More Information

Article History

Received: 1 June 2025

Revised: 22 February 2026

Accepted: 17 March 2026

First Online: 6 May 2026

Competing interests

: The corresponding author received research funds from Onconic Therapeutics. The remaining authors declare no conflict of interest.

: All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of CHA University (IACUC 2220054). All methods were performed in accordance with the relevant guidelines and regulations.

: The collection of patients’ samples was approved by the Institutional Review Board (IRB) at the CHA Bundang Medical Center (IRB number: CHAMC 2016-3-037).

Document is current

Any future updates will be listed below